Fig. 1From: Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemiaOverall survival (OS) and Progression free survival (PFS) of the whole cohort to death Back to article page